Metal complexes are extensively used for cancer therapy. The multiple variables available
for tuning (metal, ligand, and metal–ligand interaction) offer unique opportunities for drug …

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT),
Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of …

The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

In the United States,[68Ga] Ga-DOTA-TOC has been approved by the Food and Drug
Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of …

Phototheranostics stem from the recent advances in nanomedicines and bioimaging to
diagnose and treat human diseases. Since tumors' diversity, heterogeneity, and instability …

Drug delivery to the brain has been one of the toughest challenges researchers have faced
to develop effective treatments for brain diseases. Owing to the blood–brain barrier (BBB) …

Introduction: Theranostics is an emerging field in which diagnosis and specific targeted
therapy are combined to achieve a personalized treatment approach to the patient. In …

Oncological diseases account for a significant portion of the burden on public healthcare
systems with associated costs driven primarily by complex and long-lasting therapies …

Nanomaterials are at the forefront of health research and development. Among different
nanomaterials, nanoparticles are especially promising for cancer theranostics. However …

Imaging procedures based on small-molecule radioconjugates targeting fibroblast activation
protein (FAP) have recently emerged as a powerful tool for the diagnosis of a wide variety of …